You are here

Acquired epilepsy in Alzheimer’s disease

Description 
Alzheimer's disease (AD) patients are 10 times more likely to develop epilepsy compared with age-matched controls. The treatment of recurrent seizures with conventional antiepileptic drugs may exacerbate cognitive decline. There are currently no treatments that prevent epilepsy in AD patients and the pathological basis for the increased risk of epilepsy is largely unknown Understanding the pathomechanisms of epileptogenesis in AD is crucial in identifying effective therapeutic strategies. This will help to prevent the development of epilepsy in this high risk and vulnerable population. This project aims to directly address the mechanisms of epileptogenesis in AD through the study of animal models of AD and acquired epilepsy. The aims will be achieved by subjecting transgenic AD models reflecting the pathological hallmarks to acquired epileptogenesis and treating them novel compounds. The phenotypic changes will be correlated with the molecular and cellular changes in these pathways.
Essential criteria: 
Minimum entry requirements can be found here: https://www.monash.edu/admissions/entry-requirements/minimum
Keywords 
Alzheimer's disease, Epilepsy, antiepileptic drugs, Translational
School 
Central Clinical School
Available options 
PhD/Doctorate
Masters by Research
Honours
BMedSc(Hons)
Time commitment 
Full-time
Physical location 
AMREP
Co-supervisors 
Assoc Prof 
Nigel Jones

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.